Sleep-wake alternation is an essential component of human biological rhythms, and physiological processes accompanying sleep are fundamental to body recovery. As reflected in waking performance, sleep is one of the major determinants of brain function. Quality of life, productivity, health, and effective education all depend on the quality of normal brain function. However, the economic and social development in our modern society has led, and will lead, to chronic disruption of sleep in a sizeable proportion of the population. The main contributors to these disruptions can be classified as either environmental (noise and light pollution), economic/societal (shift-work schedule), or pathological (sleep disorders). The detrimental effects of these factors on sleep increase with age and are expected to have an even larger impact in the future, given the aging population and the increased prevalence/incidence of shift work.

Sleep laboratory investigations constitute a unique noninvasive tool to analyze brain functioning. Polysomnographic recordings, even in the very early phase of development in humans, are mandatory in a developmental plan of a new sleep-acting compound. Sleep is also an interesting tool for the development of other drugs acting on the central nervous system (CNS). Indeed, changes in sleep electroencephalographic (EEG) characteristics are a very sensitive indication of the objective central effects of psychoactive drugs, and these changes are specific to the way the drug acts on the brain neurotransmitter systems. Moreover, new compounds can be compared with reference drugs in terms of the sleep EEG profile they induce. For instance, cognitive enhancers involving cholinergic mechanism have been consistently demonstrated to increase rapid eye movement (REM) sleep pressure, and studying drug-induced slow wave sleep (SWS) alteration is a particularly useful tool for the development of CNS compounds acting at the 5-HT2A/C receptor, such as most atypical antipsychotics and some antidepressant drugs. The sleep EEG profile of antidepressants, and particularly their effects on REM sleep, are specific to their ability to enhance noradrenergic or serotonergic transmission. It is suggested that the effects of noradrenergic versus serotonergic reuptake inhibition could be disentangled using specific monoamine depletion tests and by studying drug effects on sleep microstructure.
At the present time, as much as one third of the adult population reports difficulty sleeping,1-3 and sleep disturbance is considered as the second most common symptom of mental distress.4 The widespread use of prescribed hypnotic medication as well as nonprescription remedies is an indirect reflection of the high frequency of sleep complaints.2,5 Sleep disorders are often chronic conditions: one study found that over 40% of those reporting sleep problems had had them for more than 5 years.1 Individuals reporting disturbed sleep are more likely to report emotional distress and recurrent health problems.1 A major prospective investigation suggests that these problems are the consequence and not the cause of sleep difficulties.6 Deviant sleep patterns have also been identified as a potentially important problem for physical health. Those who report shorter average sleep duration (“short-sleepers”) as well as those reporting long sleep duration (“long-sleepers”) have been shown to have an increased risk of mortality.7-9 Despite recent inroads into understanding of the sleep-regulatory neural circuit,10-13 current treatments for sleep disorders act via a limited number of pathways. Most hypnotics target GABAergic (GABA, γ-aminobutyric acid) activity globally in the brain. Other commonly used hypnotics that were not designed to treat insomnia (sedative antidepressants and antihistamines) have long half-lives and peripheral side effects. Current treatments for hypsomnias typically enhance dopaminergic transmission. New drugs designed for treating restless legs syndrome and periodic limb movement during sleep are needed. In a similar way, studies are needed to understand why most sedatives exacerbate disordered breathing during sleep, and to design countermeasures, or even drugs preventing, sleep apnea. As recently stressed by Mignot et al,14 the rapid growth of basic and clinical sleep research promises to lead to new and more targeted pharmacotherapy for sleep disorders. Thus, new drugs for therapeutic application in sleep disorder medicine are clearly needed. For this purpose, objective assessments of drug effects with polysomnographic recordings, even in the very early phase of development in humans, are mandatory in a developmental plan for a new sleep-acting compound. In the present paper, arguments for using sleep as a tool for the development of other drugs acting on the central nervous system (CNS) will be presented. In the following sections, we will discuss how the relationship between sleep physiology and neurotransmitter function could be used for the development of CNS-acting drugs.

**REM sleep pressure as a surrogate marker of a cognitive enhancer acting on cholinergic neurotransmission**

The cholinergic system is one of the most important modulatory neurotransmitters in the brain and controls many activities that depend on selective attention and conscious awareness. Drugs that antagonize muscarinic receptors induce hallucinations and reduce the level of consciousness, while the nicotinic receptor is implicated in the mode of action of general anesthetics.14 In degenerative diseases of the brain, such as Alzheimer’s disease, dementia with Lewy bodies, or Parkinson’s disease, alterations in consciousness, loss of memory, visual hallucinations, or rapid eye movement (REM) sleep abnormalities have been associated with regional deficits in the cholinergic system. In the following sections, we will briefly discuss the value of using REM sleep as a surrogate marker of compounds acting on cholinergic neurotransmission, and particularly in the development of cognitive enhancers for Alzheimer’s disease.

**REM sleep**

REM sleep was first described in 1953 by Aserinsky and Kleitman.15 At regular 90- to 100-min intervals, they observed the spontaneous emergence of electroencephalographic (EEG) desynchronization accompanied by clusters of rapid saccadic eye movements. When subjects were awakened during such an episode, they generally reported that they had been dreaming. REM sleep is also called paradoxical sleep because of the close resemblance to the EEG of active wakefulness combined...
with a “paradoxical” active inhibition of major muscle groups that seems to reflect deep sleep. Normal sleep is characterized in EEG terms as recurrent cycles of non-REM and REM sleep of about 90 min. Non-REM sleep is subdivided into stages 1 through 4, with stage 1 being the lightest and stage 4 being the deepest sleep. In the successive cycles of the night, the amounts of stages 3 and 4 (also known as slow wave sleep [SWS]) decrease, and the proportion of the cycle occupied by REM sleep tends to increase, with REM episodes occurring late in the night having more eye movement bursts than REM episodes occurring early in the night.

Disturbances in REM sleep organization can be assessed by measuring its total amount (expressed in minutes or as a percentage of total sleep time), its onset latency (REM latency), its distribution across the successive non-REM/REM cycles during the night, and the actual number of rapid eye movements (REM activity) during this sleep stage or per minute of REM sleep (REM density). For instance, an increased propensity for REM sleep (or increased REM sleep pressure) is described as a greater amount of REM sleep mostly at the beginning of the night (also reflected by a shortened REM latency) and an increase in REM activity and REM density.

**Acetylcholine, REM sleep, and Alzheimer’s disease**

At the present time, there is clear evidence for cholinergic mechanisms in the generation of REM sleep, and this has been the subject of many studies for the last four decades. Animal studies have demonstrated that the expression of REM sleep-related physiology (eg, thalamocortical arousal, pontogeniculate-occipital waves, and atonia) depends upon a subpopulation of brain stem pediculopontine tegmental neurons that release acetylcholine to act upon muscarinic receptors. Since a variable degree of cell loss in the pediculopontine region has been reported in Alzheimer’s disease, it is tempting to speculate that the cholinergic deficit induces REM sleep-specific abnormalities such as decreased REM duration and density, increased REM latency, and REM sleep behavior disorder.

More generally, human studies indicate that acute administration of muscarinic cholinergic agonists increase REM sleep propensity, whereas acute administration of muscarinic antagonists produce the opposite effect. Based upon the pharmacological profile of the compounds used to manipulate sleep, it appears that both M1 and M2 muscarinic receptor subtypes are involved in REM sleep regulation. Regarding acetylcholinesterase inhibitors, studies in healthy volunteers have shown that phystostigmine, tacrine, and rivastigmine increase REM sleep pressure. Interestingly, another acetylcholinesterase inhibitor, donepezil, may have a role in the treatment of REM sleep behavior disorder, a syndrome characterized by the appearance of elaborated motor activity associated with dream mentation due to the intermittent loss of REM sleep muscular atonia.

In summary, the study of REM sleep propensity in normal subjects is a particularly useful tool in the development of CNS agents acting on cholinergic neurotransmission. This has been recently exemplified by studies using REM sleep changes as surrogate markers of the activity of acetylcholinesterase inhibitors. Drugs enhancing cholinergic transmission have been consistently demonstrated to increase REM sleep pressure. In this regard, cognitive enhancers involving a cholinergic mechanism have been shown to increase REM sleep amount, to shorten REM latency, and to increase REM activity and density. These characteristics are the sleep EEG “signature” of this class of drugs and could thus represent surrogate markers of activity.

**Aging, SWS, and 5-HT2 receptor antagonism**

**Role of SWS**

It has long been assumed that sleep per se is essential for the restoration of body and mind; research conducted over the past three decades has led many experts to assume that SWS is centrally involved in such restorative process. In support of this assumption are numerous studies showing that SWS is totally recovered following sleep deprivation, as well as several investigations linking SWS to growth hormone (GH) secretion, which contributes to tissue repair. For instance, in monkeys, a positive correlation between the duration of SWS and the level of cerebral protein synthesis has been demonstrated.

Investigations of sleep-related changes in heart rate and blood pressure that found indices of parasympathetic dominance during non-REM sleep and particularly SWS, and positron emission tomography (PET) scan studies showing that global cerebral glucose metabolism in humans is lowest in SWS, are findings that further suggest a role of SWS in body restoration.
Further evidence for a role of SWS in human somatic restoration comes from studies showing that SWS increases following daytime exercise and from the study of Kattler et al showing that, in humans, slow wave activity increases during SWS in the central area contralateral to a prolonged vibratory hand stimulation experienced during the previous waking period. Regarding mental restorative processes, results of studies investigating the role of sleep in learning and memory suggest that memory formation is prompted by SWS-related processes with REM sleep promoting memory formation at a second stage (recently reviewed in references 10 and 36). In this regard, some studies suggested that cognitive performance (assessed through reaction time tasks) is related to amounts of SWS in healthy young volunteers or to specific slow wave deficiencies in older insomniacs.

Aging and SWS

Normal aging is characterized by the occurrence of several sleep disturbances. Polysomnographic recordings identify an increase in the number and duration of awakenings during sleep and a lowering of SWS. Nocturnal sleep is found to be less restorative, and aged subjects are prone to insomnia, daytime somnolence, and napping. Finally, since many aspects of cognitive performance decline with aging, it seems reasonable to question the relationship between SWS and cognitive performance among older adults. It has been hypothesized that the amount of SWS could be directly related to the efficiency of neuronal connections in the cortex and that aging leads to a decrease in the physiological process (process S) inducing SWS and favoring sleep continuity.

5-HT2 receptor and SWS

A body of evidence suggests that serotonergic transmission, particularly at the level of the 5-HT2A/C receptor, plays a major role in the induction of process S and SWS. Drugs antagonizing the 5-HT2A/C receptor increase SWS, whereas 5-HT2A/C agonists have the opposite effect. Spectral analysis of non-REM sleep shows a huge increase in slow wave activity with compounds blocking 5-HT2A/C transmission. Although some antidepressant and antipsychotic drugs display this 5-HT2A/C antagonist profile and indeed have been shown to increase SWS, up to now there is no drug marketed for sleep disorder that enhances SWS in a sustained manner. In contrast, chronic benzodiazepine administration has been shown to decrease SWS. New nonbenzodiazepine hypnotics acting at the GABA_A receptor, such as zolpidem, have a more favorable profile in terms of sleep architecture, although none of them has demonstrated sustained SWS enrichment after repeated administration.

In this regard, 5-HT2A/C receptor antagonists could thus be of great interest for alleviating age-related sleep disturbances and for ameliorating psychomotor and cognitive functions by restoring deep SWS, particularly in elderly insomniacs. There is preliminary evidence to suggest that repeated administration of ritanserin 5 mg (a 5-HT2A/C receptor antagonist) in middle-aged poor sleepers decreases the frequencies of awakening and improves subjective quality of sleep and increases subjective alertness in narcoleptic patients and in young healthy volunteers performing a driving test. Furthermore, in young healthy subjects, Gronfier et al found that the SWS enrichment induced by the acute administration of ritanserin 5 mg is positively correlated to the amount of GH secretion, suggesting a common 5-HT2A/C–triggered stimulatory mechanism between GH secretion and delta wave activity.

The question of whether antagonizing the 5-HT2A or 5-HT2C receptor allows SWS enhancement is still unresolved. There are some data suggesting that 5-HT2C mediates SWS, but Landolt et al showed substantial SWS enhancement with SR 46349B, a specific 5-HT2A antagonist. Clozapine, which displays a weaker activity for 5-HT2A receptors, does not seem to affect SWS in schizophrenic patients or even tends to diminish it. Olanzapine induces clear-cut SWS enhancement in healthy subjects; these effects seem to be mediated by 5-HT2C receptors, since allelic differences in the gene coding for this receptor influence SWS responses to olanzapine. In summary, compounds antagonizing 5-HT2A/C receptors could be valuable drugs for age-related sleep disturbances. In healthy subjects, studying drug-induced SWS alteration is a particularly useful tool for the development of CNS-acting compounds with 5-HT2A/C–blocking properties.

REM sleep alterations as surrogate markers of antidepressant responsive conditions

Characteristic sleep EEG changes have been consistently identified in depressive illness. Lengthening of
sleep latency, frequent nocturnal awakening, and early morning wakening resulting in a decrease in total sleep time are the hallmarks of sleep continuity disturbances in major depression. With regard to sleep architecture, a deficit of SWS, especially during the first sleep cycle, has been consistently described. Disturbances in REM sleep organization consist of an earlier onset of this sleep stage, a greater amount of REM sleep at the beginning of the night, and an increase in the actual rapid eye movements (REM activity and REM density) during this sleep stage.64,65 There is some evidence that these sleep abnormalities increase with the severity of the depression66,67 and that they are more pronounced in older patients.41,68 Furthermore, some studies, which controlled for the effects of these variables, indicate a comparable sleep EEG in different depressive subtypes, including the bipolar/unipolar distinction,69 but suggest a role for endogenous and psychotic symptoms in the appearance of shortening of REM latency.70,71

Although the specificity of this sleep EEG profile to depression is not fully established, it should be noted that, according to Benca et al,72 the most widespread and the most severe disturbances are found in patients with depressive disorder. Furthermore, REM sleep alterations have been reported in antidepressant-responsive conditions such as obsessive-compulsive disorder,73 panic disorder,74 depressed patients with anorexia nervosa75 or alcoholism,76 and, by some authors, in nondepressed patients with schizophrenia.77 Thus, a body of evidence suggests that REM sleep disturbances could relate to antidepressant-responsive psychopathological states. It has been hypothesized that an imbalance between aminergic and cholinergic influences underlie REM sleep disinhibition (earlier onset, greater amount in the first part of the night, increase in the number of rapid eye movements) in depressive disorder.78 Conversely, the ability of most antidepressant drugs to inhibit REM sleep might be attributed to facilitation of noradrenergic and/or serotonergic function or to muscarinic blockade.53 In some cases, as with most tricyclic antidepressants, all three mechanisms may be involved. Antidepressant drugs without clear-cut REM suppressant effects (ie, amineptine, bupropion, nefazodone, tianeptine, trazodone, and trimipramine) have a common characteristic: their potency for inhibiting adrenergic or serotonergic uptake is either absent or moderate.79,80

Modeling a specific serotonergic and noradrenergic depressive profile by acute monoamine depletion

Serotonergic and catecholaminergic neurotransmission depletion paradigms have been shown to be useful research tools to evaluate the role of these neurotransmitter systems, both in the pathogenesis of depression and in the mechanisms of antidepressant treatment modalities.61 It is postulated that sleep EEG disturbances in response to serotoninergic and catecholaminergic challenges reflect pathologically diminished levels of serotonin or catecholamine release in depression, a condition that could briefly be elicited in healthy subjects with these depletion procedures. The only study to have tackled the question lends support to the idea that the tryptophan depletion test (TDT) in healthy subjects can mimic depressed patients in terms of neuroendocrine response to serotoninergic challenge; indeed, after performing a TDT in healthy subjects, Coccaro et al82 showed an attenuated prolactin response to fenfluramine. Some studies83-86 suggest that the TDT might be a valuable procedure to elicit typical sleep abnormalities of depression, and, in particular, an increased REM sleep pressure, a condition assumed to be associated with response to antidepressant drugs. It can be thus postulated that the TDT challenges using REM sleep pressure as a surrogate marker of depression might be useful models for studying the mechanisms of action of antidepressant drugs, since acute or chronic antidepressant drug administration should interfere with these sleep alterations. Indeed, in a recent study, we were able to demonstrate that the effects of the serotonin reuptake inhibitor fluvoxamine on REM sleep were partially inhibited by TDT challenge. Further developments of this technique will include a study with a specific noradrenergic reuptake inhibitor and the phenylalanine depletion challenge, and an attempt to replicate the sleep animal data suggesting that specific monoamine depletion could identify noradrenaline and serotonin reuptake inhibitors.87

Distinguishing the effects of SNRIs from those of SSRIs on the basis of sleep EEG recordings

Selective serotonin reuptake inhibitors (SSRIs), selective noradrenaline reuptake inhibitors (SNRIs), and dual noradrenaline and serotonin reuptake inhibitors (NSRIs) have all shown an REM-suppressant effect after single or repeated administration to healthy volunteers (for recent
reviews of the effects of antidepressants on sleep see references 52 and 88). There are also studies suggesting that these three types of antidepressant exhibit alerting effects (ie, tend to enhance vigilance and therefore induce arousal during sleep), although data are more sparse for SNRI and particularly NSRI. We suggest that sleep microarchitecture could distinguish SSRI from SNRI. Up to now, very few studies have investigated the effects of antidepressant drugs on the EEG spectral power values. For instance, the NSRI venlafaxine has been shown to decrease the power of delta and theta waves and increase fast beta-activities during non-REM sleep in depressed patients, suggesting that this compound could lighten sleep intensity. Other studies in depressed patients showed that citalopram decreased the non-REM EEG power in the 8 to 9 Hz range (lower alpha waves) and trazodone decreased the non-REM EEG power in the 13 to 14 Hz range (lower beta waves). One study in healthy subjects did not reveal any change in spectral power values in the delta, theta, alpha, beta, and gamma frequency ranges after 4 weeks of paroxetine administration. There are some indications in the literature suggesting that serotonin and noradrenaline may play a different role in the regulation of sleep; indeed noradrenaline could be implicated in wake-promoting mechanisms and hyper-arousal, whereas serotonin could be more involved in sleep-promoting mechanisms. For instance, animal studies suggest that noradrenaline and serotonin microinjections in the basal forebrain induce different modulation of gamma EEG activity and of the sleep-wake state. It can thus speculated that sleep microstructure, reflecting these specific mechanisms, could be differently affected by the single administration of an SSRI, an SNRI, or an NSRI.

In summary, the sleep EEG profile of antidepressants and particularly the effects on REM sleep are specific to their ability to enhance noradrenergic or serotoninergic transmission. It is suggested that the respective effects of noradrenergic versus serotoninergic reuptake inhibition could be disentangled using specific monoamine depletion tests and by studying drug effects on sleep microstructure.

**Conclusions**

Sleep EEG recordings constitute a unique noninvasive tool to analyze brain functioning. The dynamic relationships between brain neurotransmitter systems can be directly addressed through the assessment of sleep physiology. Neurotransmission disturbances, such as those encountered in mental disorders, are reflected in spontaneous alteration of sleep continuity and architecture, or in aberrant sleep EEG responses to the administration of specific neuropsychopharmacological probes. Sleep laboratory investigations are particularly well suited to evaluating objective effects of psychoactive drugs on sleep and wakefulness. Moreover, new compounds can be compared with reference drugs in terms of the sleep EEG profile they induce. Finally, all-night sleep EEG spectral analysis provides a matchless technique to study the way drugs affect sleep microstructure, and therefore the core of sleep regulation mechanisms.

**REFERENCES**

1. Bixler EO, Kales A, Soldatos CR, Kales JD, Healy S. Prevalence of sleep disorders in the Los Angeles metropolitan area. *Am J Psychiatry*. 1979;136:1257-1262.

2. Mellinger GD, Balter MB, Uhlenhut EH. Insomnia and its treatment. Prevalence and correlates. *Arch Gen Psychiatry*. 1985;42:225-232.

3. Ohayon MM. Epidemiological study on insomnia in a general population. *Sleep*. 1996;57-515.

4. National Center for Health Statistics. Selected symptoms of psychological distress. *US Public Health Service Publication 1000*, series 11, Number 37, US Department of Health, Education and Welfare: Washington, DC; 1970.

5. Balter MB, Bauer ML. Patterns of prescribing and use of hypnotic drugs in the United States. In: Clift AD, ed. *Sleep Disturbances and Hypnotic Drug Dependence*. New York, NY: Excerpta Medica; 1975.

6. Johnson LC, Spinweber CL. Quality of sleep and performance in the navy: a longitudinal study of good and poor sleepers. In: Guilleminault C, Lugaresi E, eds. *Sleep/wake Disorders: Natural History, Epidemiology and Long-term Evolution*. New York, NY: Raven Press; 1983:13-28.

7. Hammond E, Garfinkel L. Coronary heart disease, stroke and aortic aneurysm. Factors in the etiology. *Arch Environ Health*. 1969;19:167-182.

8. Belloc NB. Relationship between health practice and mortality. *Prev Med*. 1973;2:67-81.

9. Kripke DF, Garfinkel L, Wingard DL, Kauber MR, Marler MR. Mortality associated with sleep duration and insomnia. *Arch Gen Psychiatry*. 2002;59:131-136.

10. Sejnowski TJ, Destexhe A. Why do we sleep? *Brain Res*. 2000;886:208-223.

11. Steriade M. Corticothalamic resonance, states of vigilance and mentation. *Neuroscience*. 2000;101:243-276.

12. Saper CB, Chou TC, Scammel TE. The sleep switch: hypothalamic control of sleep and wakefulness. *Trends Neurosci*. 2001;24:726-731.
Los mecanismos del sueño-vigilia y el descubrimiento de fármacos: el EEG de sueño como una herramienta para el desarrollo de fármacos que actúan sobre el SNC

Las investigaciones de laboratorio de sueño constituyen una herramienta única, no invasora, para analizar el funcionamiento cerebral. Los registros polisomnográficos son mandatorios dentro del plan de desarrollo de un nuevo compuesto que actúe sobre el sueño, aun en la fase muy precoz del desarrollo en humanos. El sueño es también una herramienta interesante para el desarrollo de otros fármacos que actúan sobre el sistema nervioso central (SNC). Verdaderamente, los cambios en las características electroencefalográficas (EEG) del sueño representan una indicación muy sensible de los efectos centrales objetivos de fármacos psicofármicos. Estos cambios son específicos en relación a la forma de actuación del fármaco en los sistemas de neurotransmisión central. Sin embargo, los nuevos fármacos se pueden comparar con fármacos de referencia en términos del perfil EEG de sueño que ellos inducen. Por ejemplo, se ha demostrado consistentemente que los “aumentadores cognitivos” al incluir mecanismos colinérgicos incrementan la carga de sueño con movimientos oculares rápidos (MOR), y el estudio de la alteración en el sueño de ondas lentas inducida por fármacos es una herramienta particularmente útil para el desarrollo de compuestos para el SNC que actúan a nivel de receptores 5-HT_{2A/C} como la mayoría de los antipsicóticos atípicos y algunos fármacos antidepresivos. El perfil EEG de sueño de los antidepresivos y, particularmente, los efectos sobre el sueño MOR son específicos en su capacidad para aumentar la transmisión noradrenérgica o serotonínica. Se ha sugerido que los efectos particulares de la inhibición de la recaptación noradrenérgica versus la inhibición de la recaptación serotonínica podrían ser aclarados utilizando pruebas específicas de depleción de monoaminas y mediante el estudio de los efectos de fármacos en la microestructura del sueño.

Mécanismes de veille-sommeil et découverte de médicaments : l’EEG de sommeil comme outil pour le développement de molécules agissant sur le SNC

L’exploration du sommeil en laboratoire constitue un outil non invasif remarquable d’analyse du fonctionnement cérébral. Les enregistrements polysomnographiques, même dans la phase très précoce du développement chez l’homme, sont impératifs dans le plan de développement d’une nouvelle molécule agissant sur le sommeil. L’exploration du sommeil est également un outil intéressant pour le développement d’autres médicaments agissant sur le système nerveux central (SNC). Les modifications des caractéristiques de l’électroencéphalogramme (EEG) au cours du sommeil sont en effet une indication très sensible des effets centraux objectifs des molécules psychoactives, et ces modifications sont spécifiques du mode d’action de la molécule sur les neurotransmetteurs cérébraux. De plus, les nouveaux traitements peuvent être comparés aux molécules de référence d’après le profil d’EEG de sommeil qu’ils induisent. Ainsi, les molécules améliorant la cognition par le biais du système cholinoergique ont régulièrement démontré qu’elles augmentaient la propension aux mouvements oculaires rapides (MOR) durant le sommeil. L’étude des altérations du sommeil à ondes lentes induites par les médicaments est particulièrement utile pour le développement de molécules du SNC agissant au niveau du récepteur 5-HT_{2A/C} tels la plupart des antipsychotiques atypiques et certains antidépresseurs. Le profil d’EEG de sommeil des antidépresseurs, et particulièrement les effets sur les MOR du sommeil, sont spécifiques de leur capacité à augmenter la transmission noradrénérgique ou sérotoninergique. Il est suggéré que les effets respectifs de l’inhibition de la recapture noradrénérgique et de l’inhibition de la recapture de la sérotonine pourraient être démêlés grâce à des tests spécifiques de déplétion des monoamines et en étudiant les effets des traitements sur la microstructure du sommeil.
13. Mignot E, Taheri S, Hishino S. Sleeping with the hypotalamus: emerging therapeutics targets for sleep disorders. Nat Neurosci. 2002;5:1071-1075.

14. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neuro-transmitter correlate of consciousness? Trends Neurosci. 1999;22:273-280.

15. Aserinsky E, Kleitman N. Regularly occurring episodes of eye motility and concomitant phenomena during sleep. Science. 1953;118:273-274.

16. Jouvet M. The role of monoamines and acetylcholine containing neurones in the regulation of sleep waking cycle. Ergebnisse der Physiologie. 1972;64:166-307.

17. Shiromani PJ, Gillin JC, Henrikson SJ. Acetylcholine and regulation of REM sleep: basic mechanisms and clinical implication for affective disorder and narcolepsy. Annu Rev Pharmacol Toxicol. 1987;27:137-156.

18. Hobson AJ, Stickgold R, Pare-Schott EF. The neurophysiology of REM sleep dreaming. Neuronreport. 1998;9:R1-14.

19. Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep. 1997;20:757-788.

20. Rao U, Lutchningshing P, Poland RE. Age-related effects of scopolamine on REM sleep regulation in normal control subjects: relationship to sleep abnormalities in depression. Neuropsychopharmacology. 1999;21:723-730.

21. Sitaram N, Mendelson WB, Wyatt RJ, Gillin JC. The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res. 1977;122:562-567.

22. Riemann D, Lis S, Fritsch-Montoro R, et al. Effect of tetrahydroaminoacridine on sleep in healthy subjects. Biol Psychiatry. 1996;39:796-802.

23. Holzboer-Trachsler E, Hatzinger M, Stohler R, et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology. 1993;8:87-92.

24. Schredl M, Weber B, Braus D, Heuser E. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol. 2000;35:243-249.

25. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000;55:870-871.

26. Tilley AJ, Wilkinson RT. The effects of a restricted sleep regime on the sleep in elderly healthy subjects. J Sleep Res. 2001;10:253-264.

27. Takahashi Y, Kipnis DM, Hening WA. Westmoreland's Syndrome: the role of a 5-HT2 receptor antagonist in the treatment of insomnia. Ann Pharmacother. 1996;30:680-691.

28. Adam K, Oswald I. Protein synthesis, bodily renewal and the sleep-wake cycle. Rev Physiol Biochem Pharmacol. 1978;53:147-450.

29. Bunnell DE, Bevier W, Horwarth SM. Effects of exhaustive exercise on slow wave sleep in healthy females and males: an EEG study. EEG Clin Neurophysiol. 1989;72:124-128.

30. Crenshaw MC, Edinger JD. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav. 1999;66:485-492.

31. Miles LE, Dement WC. Sleep and aging. Sleep. 1980;3:119-220.

32. Agnew HW, Webb WB, Williams RL. Sleep patterns in late middle age: an EEG study. EEG Clin Neurophysiol. 1967;23:168-171.

33. Knowles JB, McLean AW. Age-related changes in sleep in depressed and healthy subjects: a meta-analysis. Neuropsychopharmacology. 1990;3:257-259.

34. Carlskodan MA, Brown ED, Dement WC. Sleep fragmentation in the elderly: relationship to daytime sleep tendency. Neurobiol Aging. 1982;3:321-327.

35. Prinz PN. Sleep patterns in healthy aged: relationship with intellectual function. J Gerontol. 1977;32:179-186.

36. Feinberg I. Changes in sleep cycle patterns with age. J Psychiatry Res. 1974;10:283-306.

37. Borbely AA. A two process model of sleep regulation. Hum Neurobiol. 1982;1:195-204.

38. Dijk DJ, Duffy JF, Czeisler CA. Age-related increase in awakenings: impaired consolidation of nonREM sleep at all circadian phases. Sleep. 2001;24:565-577.

39. Jouvet M, Denoeyer M, Kitaama K, Samanoua M. Slow wave sleep and indolamines: a hypothalamic target. In: Wauquier A, Dugovic C, Radulovacki, eds. Slow Wave Sleep. Physiological, Pathophysiological and Functional Aspects. New York, NY: Raven Press; 1989:91-107.

40. Sharpley AL, Cowen PJ. Effects of pharmacologic treatment on the sleep of depressed patients. Biol Psychiatry. 1995;37:85-98.

41. Landolt HP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology. 1999;21:455-460.

42. Viola AU, Brandenberger G, Toussaint M, Bouhous P, Macher JP, Luthringer R. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmity in young poor sleepers. Clin Neurophysiology. 2002;113:429-434.

43. Nicolaou AN, Bradley CM, Pascoe PA. Medication effects on sleep and wakefulness. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia, Pa: Saunders; 1989.

44. Staner L, Luthringer R, Macher JP. Effects of antidepressive drugs on sleep EEG in patients with major depression. Mechanisms and therapeutic implications. CNS Drugs. 1999;11:49-60.

45. Gaillard JM. Sommeil et psychotropes. J Pharmacol. 1984;15:289-299.

46. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32:680-691.

47. Adam K, Oswald I. Protein synthesis, bodily renewal and the sleep-wake cycle. Clin Sci. 1983;65:561-567.

48. Lammers GJ, Arends J, Dekker AC, Kamphuisen HA, Schouwink G, Troost J, Ritanserin, a 5-HT<sub>2</sub> receptor blocker, as add-on treatment in narcolepsy. Sleep. 1991;14:130-132.

49. Van Laar M, Volkers E, Verbeuten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT<sub>2</sub> antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology. 2001;154:189-197.

50. Gronfier C, Luthringer R, Follenius M, et al. A quantitative evaluation of the relationships between growth hormone secretion and delta wave electroencephalographic activity during normal sleep and after enrichment in delta waves. Sleep. 1996;19:817-824.

51. Katsuda Y, Walsch AE, Ware CJ. Effects of prolonged sleep deprivation on slow wave sleep in humans. Biol Psychiatry. 1993;33:49-51.

52. Sharpay AL, Vassalo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT<sub>2</sub> receptors in vivo. Biol Psychiatry. 2000;47:468-470.

53. Staner L, Granier F, Vandenheede F, Macher JP, Luthringer R. Repeated administration of olanzapine differentially affects slow wave sleep, sleep continuity and daytime sedation: a placebo-controlled study of morning versus evening dosing in healthy volunteers. Eur Neuropsychopharmacol. 2002;12(suppl 3):S325.

54. Lindberg N, Virkunnen M, Tani P, et al. Effect of a single-dose of olanzapine on sleep in healthy females and males. Int Clin Psychopharmacol. 2002;17:177-184.

55. Reynolds CF III, Kupfer DJ. Sleep research in affective illness: state of the art circa 1987. Sleep. 1987;10:199-215.

56. Buysse DJ, Kupfer DJ. Diagnostic and research applications of electroencephalographic sleep studies in depression: conceptual and methodological issues. J Neuropsychiatry Clin Neurosci. 1990;2:178:405-414.

57. Kupfer DJ, Ulmik CM, Grochocinski V. Relationship between EEG sleep measures and clinical ratings of depression. J Affect Disord. 1984;6:43-52.

58. Hubain P, Van Veeren C, Staner L, Mendlewicz J, Linkowski P. Neuroendocrine and sleep variables in major depressed patients: role of severity. Psychiatry Res. 1996;63:83-93.
68. Kerkhofs M, Kempenaers C, Linkowski P, De Martelaere V, Mendlewicz J. Multivariate study of sleep EEG in depression. Acta Psychiatr Scand. 1988;77:463-468.

69. Fossion P, Staner L, Dramia M, et al. Does sleep EEG data distinguish between UP, BPI or BPII depressions? An age- and gender-controlled study. J Affect Disord. 1998;49:181-187.

70. Hubain P, Souery D, Jönck L, et al. Relationship between the Newcastle scale and sleep polysonmographic variables in major depression: a controlled study. Eur Neuropsychopharmacol. 1995;5:129-134.

71. Stefos G, Staner L, Kerkhofs M, Hubain P, Mendlewicz J, Linkowski P. Shortened REM latency as a psychobiologic marker for psychotic depression? An age, gender and polarity controlled study. Biol Psychiatry. 1998;44:1314-1320.

72. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992;49:651-668.

73. Insel TR, Gillin JC, Moore A, Mendelson WB, Loewenstein RJ, Murphy DL. The sleep of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1982;39:1372-1377.

74. Uhde TW, Roy-Byrne P, Gillin JC, et al. The sleep of patients with panic disorder. A preliminary report. Psychiatry Res. 1984;12:251-259.

75. Katz JL, Kuperberg A, Pollack CP, Walsh BT, Zumoff B, Weiner H. Is there a relationship between eating disorder and affective disorder? New evidence from sleep recordings. Am J Psychiatry. 1984;141:753-759.

76. Moeller FG, Gillin JC, Irwin M, Golshan S, Kripke DF, Schuckit M. A comparison of sleep EEGs in patients with primary major depression and major depression secondary to alcoholism. J Affect Disord. 1995;37:39-42.

77. Zarcone VP Jr, Benson KL, Berger PA. Abnormal rapid eye movement latencies in schizophrenia. Arch Gen Psychiatry. 1987;44:45-48.

78. McCarley RW. REM sleep and depression; common neurobiological control mechanisms. Am J Psychiatry. 1982;139:565-570.

79. Seeman R. Receptor Tables vol 2: Dissociation Constants for Neuroreceptors and Transporters. Toronto, Canada: SZ Research; 1993.

80. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCA. J Clin Psychiatry. 1999;60:326-335.

81. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29:2-11.

82. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger R. Tryptophan depletion attenuates the prolactin response to d-fenfluramine challenge in healthy human subjects. Psychopharmacology. 1998;138:9-15.

83. Bhatti T, Gillin JC, Seifritz E, et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and sleep. Biol Psychiatry. 1998;43:52-59.

84. Moore P, Gillin JC, Bhatti T, et al. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry. 1998;55:534-539.

85. Vordeholzer U, Hornyk M, Thiel B, et al. Impact of experimentally induced serotonin deficiency by tryptophan depletion on sleep EEG in healthy subjects. Neuropsychopharmacology. 1998;18:112-124.

86. Landolt HP, Schnierow BJ, Kelsoe JR, Rappaport MH, Gillin JC. Phenelzine-induced suppression of REM sleep can be reversed by rapid tryptophan depletion. Sleep. 2000;23(suppl 2):A34.

87. Gaillard JM, de St Hilaire-Kafi S. Sleep, depression and the effects of antidepressant drugs. Acta Psychiatr Belg. 1985;85:561-567.

88. Winokur A, Gary AK, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology and antidepressant drugs. Depress Anxiety. 2001;14:19-28.

89. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull. 1996;32:637-642.

90. Van Bemmel AL, Beersma DGM, Van Den Hoofdakker RH. Changes in EEG power density of NREM sleep in depressed patients during treatment with citalopram. J Sleep Res. 1993;2:156-162.

91. Van Bemmel AL, Beersma DGM, Van Den Hoofdakker RH. Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. J Affect Disord. 1995;35:11-19.

92. Schlosser R, Roschke J, Rossbach W, Benkert O. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol. 1998;8:273-278.

93. McEven BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000;886:172-189.

94. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural circuit for circadian regulation of arousal. Nat Neurosci. 2001;4:732-738.

95. Dugovic C. Role of serotonin in sleep mechanisms. Rev Neurol (Paris). 2001;157:5516-5517.

96. Jouvet M. Sleep and serotonin: an unfinished story. Neuropsychopharmacology. 1999;21:245-275.

97. Cape EG, Jones BE. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons. J Neurosci. 1998;18:2653-2666.